Allergan Aesthetics Gains FDA Approval for SKINVIVE Neck Indication, Its Second Cleared Use

A second cleared indication for an already-approved injectable signals a lifecycle management pathway that regulatory affairs teams will want to map against their own portfolios: Allergan Aesthetics has received FDA approval to market SKINVIVE by JUVÉDERM® for reducing horizontal neck lines in adults over 21, making it the first hyaluronic acid (HA) injectable with a cleared neck-wrinkle indication.

SKINVIVE first gained FDA clearance in 2023 for improving cheek skin smoothness. The neck indication represents a supplemental approval built on a randomized, multicenter, evaluator-blinded, controlled pivotal study, a design regulatory leads will recognize as consistent with the evidentiary standard for expanded indications on previously approved injectables. In that study, 74.8% of treated participants achieved a clinically significant improvement (≥1 point) on the validated 5-grade Allergan Transverse Neck Lines Scale (ATNLS) at one month; 66% maintained that improvement threshold at six months.

The adverse event profile from the pivotal study is relevant to QA and clinical operations teams preparing post-market surveillance frameworks. Participants reported injection-site reactions including redness, bruising, tenderness, swelling, and pain; the majority were mild, resolved within two weeks, and required no intervention. Severe AEs were reported in fewer than 5% of participants. The frequency of AEs was similar or lower following touch-up and repeat treatments, a finding that bears on long-term safety monitoring obligations under 21 CFR Part 211 post-approval commitments.

As a condition of approval, the FDA has required Allergan Aesthetics to establish a mandatory provider training program; purchase and administration of the product are contingent on successful completion. For compliance and distribution teams, this requirement introduces a credentialing checkpoint that must be embedded in the commercial supply chain before the product reaches injectors. Allergan Aesthetics has indicated broad commercial availability is expected later in 2026.

The study's noted limitation, that safety and effectiveness in darker skin tone patients has not been evaluated, represents a gap that post-market study commitments may eventually need to address, and is a data point regulatory affairs leads should track as the product's real-world use expands.

Provider training completion rates and post-market safety reporting timelines will serve as the near-term measurable checkpoints for this approval's operational rollout.

Source: AbbVie News Center via PRNewswire, June 16, 2026.